The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 18 of the 89 sources its claims cite were checked for support.
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Open accessAbstract
Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the United States (Germany, n = 66; United States, n = 106; total, n = 172), we demonstrate that wide-spectrum antibiotics treatment ('high-risk antibiotics') prior to CD19-targeted chimeric antigen receptor (CAR)-T cell therapy is associated with adverse outcomes, but this effect is likely to be confounded by an increased pretreatment tumor burden and systemic inflammation in patients pretreated with high-risk antibiotics. To resolve this confounding effect and gain insights into antibiotics-masked microbiome signals impacting CAR-T efficacy, we focused on the high-risk antibiotics non-exposed patient population. Indeed, in these patients, significant correlations were noted between pre-CAR-T infusion Bifidobacterium longum and microbiome-encoded peptidoglycan biosynthesis, and CAR-T treatment-associated 6-month survival or lymphoma progression. Furthermore, predictive pre-CAR-T treatment microbiome-based machine learning algorithms trained on the high-risk antibiotics non-exposed German cohort and validated by the respective US cohort robustly segregated long-term responders from non-responders. Bacteroides, Ruminococcus, Eubacterium and Akkermansia were most important in determining CAR-T responsiveness, with Akkermansia also being associated with pre-infusion peripheral T cell levels in these patients. Collectively, we identify conserved microbiome features across clinical and geographical variations, which may enable cross-cohort microbiome-based predictions of outcomes in CAR-T cell immunotherapy.
Overview
CoChat Summary
TL;DR
In a five-center German/US lymphoma cohort, broad-spectrum antibiotics before CD19 CAR-T were linked to worse outcomes, but this appeared largely explained by greater pre-treatment tumor burden and inflammation. Among patients not exposed to those antibiotics, baseline gut microbiome features—especially Bifidobacterium longum, peptidoglycan biosynthesis, and taxa including Akkermansia—correlated with response/survival and supported cross-cohort machine-learning prediction.
Key findings
- The study enrolled 172 patients with relapsed/refractory B-cell lymphoma (Germany n=66; US n=106) across five centers; median age was 62.0 years, 55 were female and 117 male, and patients had received a median of three prior systemic therapy lines. Day-90 best overall response was 58.1% (100/172) and complete response was 47.6% (82/172).
- Any antibiotic exposure within three weeks before infusion was associated with shorter progression-free survival (HR=2.04), and the defined “high-risk antibiotics” group (meropenem, cefepime, ceftazidime, piperacillin-tazobactam) had higher progression (OR=2.60), shorter PFS (HR=3.05), and shorter overall survival (HR=2.99). High-risk antibiotic recipients also had more any-grade ICANS (23/36, 63.8%) than others (42/110, 38.2%), but they had higher LDH, metabolic tumor volume, CRP, and IL-6, plus lower peripheral CD4 T cells; in multivariate analysis, high-risk antibiotics remained associated with PFS (HR=2.19) but lost association with OS (HR=1.96).
- After excluding high-risk antibiotic-exposed samples, Bifidobacterium longum and microbiome-encoded peptidoglycan biosynthesis were associated with 6-month survival or early lymphoma progression. Machine-learning models trained on the German cohort and validated in the US cohort predicted day-180 complete response better after excluding high-risk antibiotic samples (probabilistic AUROC=0.67±0.04; deterministic AUROC=0.69) than models including all samples (probabilistic AUROC=0.52±0.05; deterministic AUROC=0.64).
- Bacteroides, Ruminococcus, Eubacterium, and Akkermansia were among the taxa most important for predicting CAR-T response; Akkermansia muciniphila abundance was also associated with pre-infusion peripheral T cell levels.
Methods
- Prospective international cohort of patients receiving CD19-targeted CAR-T therapy for B-cell lymphoma between 2018 and 2021 at three German and two US tertiary centers; products included axi-cel (n=122), tisa-cel (n=49), and liso-cel (n=1). Clinical data included antibiotic exposure in the three weeks before infusion, tumor burden markers, inflammatory markers, T cell counts, and outcomes including response at 90/180 days, PFS, OS, CRS, and ICANS.
- Stool samples were collected serially (351 samples from 116 of 172 patients) and analyzed by shotgun metagenomic sequencing, with taxonomic and functional profiling using MetaPhlAn3 and HUMAnN3. Analyses included alpha diversity, Bray-Curtis beta diversity, differential abundance, PERMANOVA, and Cox proportional hazards models.
- Prediction used supervised machine learning with the German cohort for training and the US cohort for external validation. Models included deterministic logistic regression with elastic-net regularization and a probabilistic Bayesian logistic regression, using baseline species abundances plus age and gender, and were run both with all baseline samples and after excluding high-risk antibiotic-exposed samples.
Limitations
- The paper states that sample-size differences and constraints between the German and US cohorts limited Cox proportional hazards regressions for PFS; that the observational design cannot demonstrate causality; and that center-specific antibiotic use, especially cefepime being given only in US patients, could confound microbiome signatures.
- Evident from the text: high-risk antibiotic exposure is strongly confounded by worse pre-treatment disease status, higher tumor burden, greater systemic inflammation, and lower T cell counts, so antibiotic-outcome associations should not be read as causal. Species-level survival analyses also had small per-group sample sizes and some borderline results, and no direct mechanistic validation is reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 0 Not valid · 41 Not checked · 166 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, our results suggest that administration of these classes of antibiotics constitutes a likely surrogate for poor disease status and a state of increased systemic inflammation prior to initiation of CAR-T cell therapy, as was recently suggested in cancer patients treated with other ICBs28,35.”
§ A non-antibiotic-disrupted gut microbiome associated with clinical responses to CD19-CAR-T cell cancer immunotherapy > DISCUSSION
What the sources say
- Partly supportedcites [28] Derosa, L. et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol. 29, 1437–1444 (2018). sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) considers whether antibiotic use reflects a general prognostic association rather than causing resistance in patients receiving immune checkpoint inhibitors. It does not identify antibiotic use as a surrogate for poor disease status or increased systemic inflammation; it also cites evidence suggesting a causal link. The CAR-T interpretation is the citing authors’ own conclusion, not a finding attributed to this source. (LLM, conf=0.84)
- Partly supportedcites [35] Castello, A., Rossi, S., Toschi, L. & Lopci, E. Impact of antibiotic therapy and metabolic parameters in non-small cell lung cancer patients receiving checkpoint inhibitor. J. Clin. Med. 10, 1251 (2021). sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that antibiotic-exposed patients had greater baseline tumor burden and acknowledges that extensive disease could increase infection risk and, in turn, antibiotic use. It does not establish increased systemic inflammation in the antibiotic group: the higher NLR trend was not significant. It also entertains a harmful effect of antibiotics, rather than concluding that antibiotic use is a surrogate instead of a cause; the study concerns checkpoint inhibitors in lung cancer, not CAR-T therapy. (LLM, conf=0.85)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For instance, broad-spectrum antibiotic treatment reduced the intestinal abundances of microbes in our patients such as Roseburia, Bifidobacterium or Ruminococcus spp., which were previously associated with beneficial outcomes of ICB cancer immunotherapies1,36.”
§ A non-antibiotic-disrupted gut microbiome associated with clinical responses to CD19-CAR-T cell cancer immunotherapy > DISCUSSION
What the sources say
- Could not verifycites [1] Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018). sourceExperimental — accuracy not yet measured
The paper’s gut-microbiome findings associate Ruminococcaceae and Faecalibacterium with favorable anti-PD-1 outcomes, but do not report that broad-spectrum antibiotics reduced Roseburia, Bifidobacterium, or Ruminococcus in patients. Searches for antibiotic exposure and the named taxa found no passage addressing the quoted reduction; the antibiotic result is described in the citing sentence as occurring in the citing authors’ own patients. (LLM, conf=0.76)
- Partly supportedcites [36] Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535–544 (2022). sourceExperimental — accuracy not yet measured
The Results section (‘Few reproducible biomarkers of response across cohorts’; page unavailable) associates Roseburia species and Bifidobacterium pseudocatenulatum with ICI responders. It instead identifies Ruminococcus gnavus as a biomarker of nonresponders, so the cited paper does not support grouping Ruminococcus with microbes associated with beneficial outcomes. The antibiotic-related reduction is presented as the citing authors’ finding, not a finding attributed to this source. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Of note in our study, we observed center-specific differences in the use of broad-spectrum antibiotics. Specifically, cefepime was only administered in US patients, which could confound microbiome signatures given its narrower anti-microbial activity spectrum as compared to other high-risk antibiotics43.”
§ A non-antibiotic-disrupted gut microbiome associated with clinical responses to CD19-CAR-T cell cancer immunotherapy > DISCUSSION
What the sources say
- Partly supportedcites [43] Gamage, H. et al. Third generation cephalosporins and piperacillin/tazobactam have distinct impacts on the microbiota of critically ill patients. Sci. Rep. 11, 7252 (2021). sourceExperimental — accuracy not yet measured
Our copy of Gamage et al. (2021) supports only the general premise: the Introduction states that 'different antibiotics vary in the spectrum of activity... Some antibiotics may be more harmful to the microbiota than others', and the Results attribute site-specific compositional differences to 'the weaker antimicrobial activity of 3GC against Enterococcaceae than TZP'. It does not support the cefepime-specific part of the attribution — cefepime was not studied here (the trial compared third-generation cephalosporins and piperacillin/tazobactam in ICU patients in two Sydney hospitals, Australia), and no passage describes cefepime as having a narrower spectrum than other high-risk antibiotics; cefepime appears only in the titles of referenced works (refs 3 and 33). Nothing in our copy addresses centre-specific or country-specific differences in antibiotic prescribing as a confounder of microbiome signatures. (LLM, conf=0.68)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer immunotherapy.”
§ A non-antibiotic-disrupted gut microbiome associated with clinical responses to CD19-CAR-T cell cancer immunotherapy > Abstract
What the sources say
- Supportedcites [1] Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018). source
The paper’s concluding passage states that the gut microbiome may modulate responses to anti-PD-1 immunotherapy in melanoma patients. This directly supports the citing sentence’s hedged claim; the supplied copy does not provide page numbers. (LLM, conf=0.94)
- Not checked yetcites [2] Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018). source
- Supportedcites [3] Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018). source
The paper reports an association between gut microbial composition and response to anti–PD-1 therapy in metastatic melanoma patients. It also reports that anti–PD-L1 treatment worked better in mice given microbiota from responding patients. These findings support the hedged claim that the gut microbiome may modulate cancer immunotherapy efficacy. (LLM, conf=0.94)
hedgedstates a possible causen = 172- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we also performed an immunological characterization of patient T cells at apheresis and found a significant reduced number of effector/effector memory CD 4 and CD8 T cells in high-risk antibiotics-treated patients”
§ A non-antibiotic-disrupted gut microbiome associated with clinical responses to CD19-CAR-T cell cancer immunotherapy > Results > Antibiotics and disease severity associated with CAR-T outcomes.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
95 more claims
Create a free account to see all 217 claims and to verify the 71 references still open.
- Probably not a substantial claim. 66
- It may state two separate claims as one. 65
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, broad-spectrum antibiotics (mainly beta-lactams) taken prior to immunotherapy markedly reduce the clinical benefit of ICIs, chimeric antigen receptor (CAR)-T cells, stem cell transplantation in patients, and immunogenic chemotherapy in preclinical tumor models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, CAR T-cells,237,238 hematopoietic stem cell transplantation,239 and vaccines244 are all affected by gut microbial composition.”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [237]
Citations
Cites
The Elements of Statistical Learning
Hastie, T., Tibshirani, R., & Friedman, J. (2009) · Springer Series in Statistics · doi:10.1007/978-0-387-84858-7 · Cited by 25,970
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationTisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Self-citationLee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Self-citationThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Self-citationBeghini, F., McIver, L. J., Blanco-Míguez, A., Dubois, L., Asnicar, F., Maharjan, S., Mailyan, A., Manghi, P., Scholz, M., Thomas, A. M., et al. (2021) · eLife · doi:10.7554/elife.65088 · Cited by 2,303
(2020) · doi:10.1101/2020.11.19.388223 · Cited by 2,303
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citation
Cited by
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Hu, Y., Hu, Q., Li, Y., Lu, L., Xiang, Z., Yin, Z., Kabelitz, D., & Wu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01653-8 · Cited by 382
Rejeski, K., Subklewe, M., Aljurf, M., Bachy, E., Balduzzi, A., Barba, P., Bruno, B., Benjamin, R., Carrabba, M. G., Chabannon, C., et al. (2023) · Blood · doi:10.1182/blood.2023020578 · Cited by 358
Self-citationBacteria in cancer initiation, promotion and progression
El Tekle, G., & Garrett, W. S. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00594-2 · Cited by 343
Ma, Z., Zuo, T., Frey, N., & Rangrez, A. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01946-6 · Cited by 259
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 265
“T cell therapy 170 (reviewed in detail elsewhere 171 ).”
Metadata
- Authors
- Stein-Thoeringer, C. K., Saini, N. Y., Zamir, E., Blumenberg, V., Schubert, M.-L., Mor, U., Fante, M. A., Schmidt, S., Hayase, E., Hayase, T., Rohrbach, R., Chang, C.-C., McDaniel, L., Flores, I., Gaiser, R., Edinger, M., Wolff, D., Heidenreich, M., Strati, P., Nair, R., Chihara, D., Fayad, L. E., Ahmed, S., Iyer, S. P., Steiner, R. E., Jain, P., Nastoupil, L. J., Westin, J., Arora, R., Wang, M. L., Turner, J., Menges, M., Hidalgo-Vargas, M., Reid, K., Dreger, P., Schmitt, A., Müller-Tidow, C., Locke, F. L., Davila, M. L., Champlin, R. E., Flowers, C. R., Shpall, E. J., Poeck, H., Neelapu, S. S., Schmitt, M., Subklewe, M., Jain, M. D., Jenq, R. R., & Elinav, E.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- German Cancer Research Center (DE)
- LMU Klinikum (DE)
- University Hospital Heidelberg (DE)
- Weizmann Institute of Science (IL)
- University Hospital Regensburg (DE)
- Leibniz Institute for Immunotherapy (DE)
- Moffitt Cancer Center (US)
- University of South Florida (US)
- Corresponding author
- Saini, Neeraj Y.
- Jain, Michael D.
- Jenq, Robert R.
- Elinav, Eran
- ORCID
- Saini, Neeraj Y.
- Zamir, Eli
- Blumenberg, Viktoria
- Schubert, Maria-Luisa
- Mor, Uria
- Fante, Matthias A.
- Hayase, Eiko
- Hayase, Tomo
- Rohrbach, Roman
- Chang, Chia-Chi
- McDaniel, Lauren
- Flores, Ivonne
- Gaiser, Rogier
- Edinger, Matthias
- Wolff, Daniel
- Strati, Paolo
- Chihara, Dai
- Fayad, Luis E.
- Ahmed, Sairah
- Iyer, Swaminathan P.
- Steiner, Raphael E.
- Jain, Preetesh
- Nastoupil, Loretta J.
- Westin, Jason
- Arora, Reetakshi
- Wang, Michael L.
- Turner, Joel
- Menges, Meghan
- Reid, Kayla
- Dreger, Peter
- Müller-Tidow, Carsten
- Locke, Frederick L.
- Davila, Marco L.
- Champlin, Richard E.
- Flowers, Christopher R.
- Shpall, Elizabeth J.
- Poeck, Hendrik
- Neelapu, Sattva S.
- Schmitt, Michael
- Subklewe, Marion
- Jain, Michael D.
- Jenq, Robert R.
- Elinav, Eran
- Venue
- Nature Medicine
- Published
- 2023-03-13
- Volume
- 29
- Issue
- 4
- Pages
- 906-916
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC10121864
- OpenAlex
- W4324044824
- Cited by
- 255
- References
- 49
- Citations by year
- 2026: 67 · 2025: 85 · 2024: 63 · 2023: 40
- FWCI
- 31.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- Funders
- Mark Foundation Endeavor Award
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- gut microbiota, CD19 CAR T-cell therapy, B-cell lymphoma, antibiotic exposure, Bifidobacterium longum, peptidoglycan biosynthesis, Akkermansia, Bacteroides, Ruminococcus, Eubacterium, treatment response prediction, peripheral T cells, systemic inflammation, tumor burden
- MeSH terms
- Gastrointestinal Microbiome, Receptors, Chimeric Antigen, Humans, Immunotherapy, T-Lymphocytes, Immunotherapy, Adoptive, Lymphoma, B-Cell, Antigens, CD19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41591-023-02234-6
- The paper
- Stein-Thoeringer, C. K., Saini, N. Y., Zamir, E., Blumenberg, V., Schubert, M.-L., Mor, U., Fante, M. A., Schmidt, S., Hayase, E., Hayase, T., Rohrbach, R., Chang, C.-C., McDaniel, L., Flores, I., Gaiser, R., Edinger, M., Wolff, D., Heidenreich, M., Strati, P., . . . Elinav, E. (2023). A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nature Medicine. https://doi.org/10.1038/s41591-023-02234-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.